A post hoc analysis of the DUO-E trial evaluated how durvalumab and maintenance olaparib influenced circulating tumor DNA dynamics in first-line endometrial cancer treatment.
A post hoc analysis of the DUO-E trial evaluated how durvalumab and maintenance olaparib influenced circulating tumor DNA dynamics in first-line endometrial cancer treatment.
A post hoc analysis of the DUO-E trial evaluated how durvalumab and maintenance olaparib influenced circulating tumor DNA dynamics in first-line endometrial cancer treatment.
A post hoc analysis of the DUO-E trial evaluated how durvalumab and maintenance olaparib influenced circulating tumor DNA dynamics in first-line endometrial cancer treatment.
A phase II trial evaluating pembrolizumab plus lenvatinib in clear cell ovarian carcinoma shows promising response rates and 6-month progression-free survival.
A phase II trial evaluating pembrolizumab plus lenvatinib in clear cell ovarian carcinoma shows promising response rates and 6-month progression-free survival.
A phase II trial evaluating pembrolizumab plus lenvatinib in clear cell ovarian carcinoma shows promising response rates and 6-month progression-free survival.
A phase II trial evaluating pembrolizumab plus lenvatinib in clear cell ovarian carcinoma shows promising response rates and 6-month progression-free survival.
A phase II trial evaluating pembrolizumab plus lenvatinib in clear cell ovarian carcinoma shows promising response rates and 6-month progression-free survival.
A phase II trial evaluating pembrolizumab plus lenvatinib in clear cell ovarian carcinoma shows promising response rates and 6-month progression-free survival.
